ImmunoPrecise Antibodies Ltd.

Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Immunoprecise Antibodies Fiscal Year 2022 Third Quarter Earnings Results and Business Highlights Call. Currently, all participants are in a listen-only mode. Following the presentation, we will answer pre-submitted questions. If anyone has any difficulties hearing the conference, please press the star key followed by the zero for operator assistance at any time. I would like to remind everyone that this conference call is being recorded today, March 16th, at 1030 a.m. Eastern Time. I will now turn the call over to John Mullaly. Mr. Mullaly, please go ahead.

Thank you and welcome. Dr. Jennifer Bath, President and Chief Executive Officer of Immunoprecise Antibodies, and Ms. Lisa Hedling, Chief Financial Officer, will be the speakers on today's call. A Q&A period answering pre-submitted questions will follow their summary of the quarter, followed by closing remarks. Before Dr. Beth begins, I've been asked by immunoprecise antibodies to read the following safe harbor regarding forward-looking statements. I would like to remind everyone that immunoprecise remarks today contain forward-looking statements about its current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or other future events or developments. In preparing these forward-looking statements, Several assumptions were made by Immunoprecise and there are risks that results may actually obtained by the company will differ materially from those statements. As a consequence, the company cannot guarantee that any forward-looking statements will materialize and you are cautioned not to place undue reliance on them. Immunoprecise refers to current potential investors to the forward-looking information section of its management discussion and analysis issued today. at www.cedr.com, and on Edgar at www.sec.gov. Forward-looking statements represent Immunoprecise's expectations as of March 16, 2022. Except as may be required by securities law, Immunoprecise does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

I would now like to turn the conference over to Dr. Bath. Thank you, John.